{"id":46894,"date":"2022-08-03T17:01:46","date_gmt":"2022-08-03T15:01:46","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/common-warts-drug-pipeline-report-2022-featuring-verrica-pharmaceuticals-x4-pharmaceuticals-phio-pharmaceuticals-kino-pharma-nielsen-biosciences-researchandmarkets-com\/"},"modified":"2022-08-03T17:01:46","modified_gmt":"2022-08-03T15:01:46","slug":"common-warts-drug-pipeline-report-2022-featuring-verrica-pharmaceuticals-x4-pharmaceuticals-phio-pharmaceuticals-kino-pharma-nielsen-biosciences-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/common-warts-drug-pipeline-report-2022-featuring-verrica-pharmaceuticals-x4-pharmaceuticals-phio-pharmaceuticals-kino-pharma-nielsen-biosciences-researchandmarkets-com\/","title":{"rendered":"Common Warts Drug Pipeline Report 2022 Featuring Verrica Pharmaceuticals, X4 Pharmaceuticals, Phio Pharmaceuticals, Kino Pharma, & NIELSEN BioSciences – ResearchAndMarkets.com"},"content":{"rendered":"
\n

DUBLIN–(BUSINESS WIRE)–The “Common Warts – Pipeline Insight, 2022”<\/a> clinical trials has been added to ResearchAndMarkets.com’s<\/strong> offering.\n<\/p>\n

<\/a><\/p>\n

\nThis ”Common Warts – Pipeline Insight, 2022,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Common Warts pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products.\n<\/p>\n

\nIt also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.\n<\/p>\n

\nThe companies and academics are working to assess challenges and seek opportunities that could influence R&D Common Warts. The therapies under development are focused on novel approaches to treat\/improve Common Warts.\n<\/p>\n

\nCommon Warts Emerging Drugs<\/strong>\n<\/p>\n

\nMavorixafor: X4 Pharmaceuticals\n<\/p>\n

\nMavorixafor as an oral, once-daily treatment for patients with WHIM syndrome. WHIM syndrome is a rare genetic primary immunodeficiency that results from “gain-of-function” mutations in the single gene that encodes for the CXCR4 receptor.\n<\/p>\n

\nVP-102: Verrica Pharmaceuticals\n<\/p>\n

\nVP-102, is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin (0.7% w\/v) delivered via a single-use applicator that allows for precise topical dosing and targeted administration. Company is developing VP-102 for the treatment of molluscum contagiosum (molluscum), common warts and external genital warts, three of the most common viral skin diseases in medical dermatology.\n<\/p>\n

\nCommon Warts: Therapeutic Assessment<\/strong>\n<\/p>\n

\nThis segment of the report provides insights about the Common Warts drugs segregated based on following parameters that define the scope of the report, such as:\n<\/p>\n

\nMajor Players in Common Warts<\/strong>\n<\/p>\n

\nThere are approx. 5+ key companies which are developing the therapies Common Warts. The companies which have their Common Warts drug candidates in the most advanced stage, i.e phase III include X4 Pharmaceuticals\n<\/p>\n

\nPhases<\/strong>\n<\/p>\n

\nThis report covers around 5+ products under different phases of clinical development like<\/strong>\n<\/p>\n